Pamrevlumab is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel (Abraxane) in the phase 3 LAPIS trial as a potential method for downgrading unresectable locally advanced pancreatic cancer (LAPC).
The phase 3 trial (NCT03941093),1 which is currently enrolling, will randomize 256 patients to receive pamrevlumab, a first-in-class inhibitor of connective tissue growth factor (CTGF) activity, or placebo with the chemotherapy doublet prior to surgery. The dual primary end points are improvement in overall survival (OS) and the portion of patients achieving R0 or R1 resection.
“Patients with unresectable LAPC face a dire prognosis. The use of pamrevlumab, a novel antifibrotic used as neoadjuvant therapy, may change tumor status from unresectable to resectable, thus potentially improving the prognosis of the patient,” Pascal Hammel, MD, PhD, a…
